Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, "Targeting cellular respiration as a therapeutic strategy in glioblastoma."
Glioblastoma cancer cells use mitochondria from the central nervous system to grow and form more aggressive tumors, according to new Cleveland Clinic-led findings published in Nature Cancer.
New multi-institutional phase 3 clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma, a deadly brain tumor.
A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 8, entitled, "Identification of dual-purpose therapeutic targets implicated in aging and glioblastoma multiforme using PandaOmics - an AI-enabled biological target discovery platform."
Cellular life hinges on a network of hollow cables called microtubules dynamically lengthening and shortening according to the needs of the moment.
Glioblastoma is the most prevalent kind of adult brain tumor.
Brain tumors are notoriously hard to treat. One reason is the challenge posed by the blood-brain barrier, a network of blood vessels and tissue with closely spaced cells.
Patients with glioblastoma-;the deadliest type of primary brain tumor-;may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.
Researchers at the University of Waterloo have created a computational model to predict the growth of deadly brain tumors more accurately.
For gene therapy, the blood-brain barrier (BBB) poses a formidable obstacle. The BBB, which is made up of cells that are closely packed together, prevents poisons and pathogens from accessing brain tissue while also blocking potential treatments for diseases that impact the CNS.
A group of Northwestern University researchers has created a novel gene editing platform that might influence the future application of a nearly infinite library of CRISPR-based therapeutics.
The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).
Patients diagnosed with a type of brain tumor survived for longer when they were treated aggressively with surgery, radiation and chemotherapy.
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.
Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule.
It is estimated that about a quarter of cancer patients are at risk of brain metastases, a rate that is increasing especially among those who suffer relapses after having undergone different cancer treatments.
For decades, a small group of cutting-edge medical researchers have been studying a biochemical, DNA tagging system, which switches genes on or off. Many have studied it in bacteria and now some have seen signs of it in, plants, flies, and even human brain tumors.
Analysis of the entire tumor RNA picks up more clinically relevant genetic changes in children with cancer than traditional diagnostic methods, new research has shown.
A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.
University of Delaware biochemist Jeff Mugridge is trying to figure out how so-called mRNA eraser enzymes work in our cells, why those erasers can sometimes misbehave and lead to cancer, and how science can pave the way for possible solutions to this problem.